SutroVax raises $22M in series A

SutroVax Inc. (South San Francisco, Calif.) raised $22 million in an oversubscribed series A round led by Abingworth. Longitude Capital; Roche Venture Fund; and CTI Life Sciences also participated.

SutroVax was spun out from Sutro Biopharma Inc. (South San Francisco, Calif.) in 2013 to develop vaccines, using an exclusive license to Sutro's Xpress CF cell-free protein synthesis platform and Xpress CF+ site-specific conjugation platform (see BioCentury, Nov. 3, 2014). ...